These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30324316)

  • 1. Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials.
    Rhee SJ; Lee HA; Lee S; Kim E; Jeon I; Song IS; Yu KS
    Pharm Res; 2018 Oct; 35(12):236. PubMed ID: 30324316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers.
    Jeon H; Lim KS; Shin KH; Kim J; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):84-91. PubMed ID: 21934629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.
    Yi S; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):682-9. PubMed ID: 21394036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects.
    Oh M; Ghim JL; Park SE; Kim EY; Shin JG
    Drug Des Devel Ther; 2018; 12():1157-1164. PubMed ID: 29780236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
    Bulitta JB; Paik SH; Chi YH; Kim TH; Shin S; Landersdorfer CB; Jiao Y; Yadav R; Shin BS
    Eur J Pharm Sci; 2017 Sep; 107():32-44. PubMed ID: 28599987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling of the pharmacokinetic/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects.
    Hedaya MA; Helmy SA
    Biopharm Drug Dispos; 2015 May; 36(4):216-31. PubMed ID: 25545238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension.
    Pandey AK; Shafiq N; Bhandari RK; Rather IIG; Kaur N; Bhatia A; Sharma S; Malhotra S
    J Hypertens; 2020 Aug; 38(8):1593-1602. PubMed ID: 32371763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Interaction Among Telmisartan, Amlodipine, and Hydrochlorothiazide After a Single Oral Administration in Healthy Male Subjects.
    Moon SJ; Jeon JY; Yu KS; Kim MG
    Clin Ther; 2019 Nov; 41(11):2273-2282. PubMed ID: 31564513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension.
    Bhad P; Ayalasomayajula S; Karan R; Leon S; Riviere GJ; Sunkara G; Jarugula V
    J Clin Pharmacol; 2011 Jun; 51(6):933-42. PubMed ID: 20852001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives.
    Angeli F; Verdecchia P; Trapasso M; Pane M; Signorotti S; Reboldi G
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):533-541. PubMed ID: 29676941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fimasartan: A New Angiotensin Receptor Blocker.
    Lee HY; Oh BH
    Drugs; 2016 Jul; 76(10):1015-22. PubMed ID: 27272555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous Analysis of a Combination of Anti-Hypertensive Drugs, Fimasartan, Amlodipine, and Hydrochlorothiazide, in Rats Using LC-MS/MS and Subsequent Application to Pharmacokinetic Drug Interaction with Red Ginseng Extract.
    Jeon SY; Jeon JH; Park JH; Lee J; Pang M; Choi MK; Song IS
    Toxics; 2022 Sep; 10(10):. PubMed ID: 36287856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects.
    Jung J; Lee S; Oh J; Lee S; Jang IJ; Lee D; Yu KS
    Transl Clin Pharmacol; 2021 Mar; 29(1):53-64. PubMed ID: 33855001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.
    Kang WY; Lee HW; Gwon MR; Cho S; Shim WS; Lee KT; Yang DH; Seong SJ; Yoon YR
    Drug Des Devel Ther; 2020; 14():2101-2111. PubMed ID: 32546973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers.
    Kang WY; Kim EH; Seong SJ; Gwon MR; Yang DH; Kim HJ; Lim MS; Lee HW; Yoon YR
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):992-1003. PubMed ID: 27668695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats.
    Kim TH; Shin S; Bashir M; Chi YH; Paik SH; Lee JH; Choi HJ; Choi JH; Yoo SD; Bulitta JB; Ma E; Joo SH; Shin BS
    Xenobiotica; 2014 Oct; 44(10):913-25. PubMed ID: 24786684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.
    Mukherjee D; Zha J; Menon RM; Shebley M
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):443-456. PubMed ID: 29427135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach.
    Ngo L; Cho HY; Lee YB
    Eur J Pharm Sci; 2018 Jun; 118():154-164. PubMed ID: 29604332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.